Teriflunomide Gets High Marks in Yet Another Phase 3 Trial
This placebo-controlled phase 3 study of oral teriflunomide for patients with relapsing MS concluded, as have previous studies, that the disease-modifying agent is safe and efficacious
This placebo-controlled phase 3 study of oral teriflunomide for patients with relapsing MS concluded, as have previous studies, that the disease-modifying agent is safe and efficacious
Evidence continues to accumulate that the disease-modifying agent teriflunomide may be a good option for...
Clinical Research